Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood. 2002 Sep 15;100(6):1965-71. doi: 10.1182/blood-2001-12-0181.
Blood. 2002.
PMID: 12200353
Free article.
Clinical Trial.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL.
Talpaz M, et al. Among authors: fernandes reese s.
Blood. 2002 Mar 15;99(6):1928-37. doi: 10.1182/blood.v99.6.1928.
Blood. 2002.
PMID: 11877262
Free article.
Clinical Trial.
Item in Clipboard
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H.
Atallah E, et al. Among authors: fernandes reese s.
Cancer. 2002 Jun 1;94(11):2996-9. doi: 10.1002/cncr.10576.
Cancer. 2002.
PMID: 12115389
Free article.
Item in Clipboard
Cite
Cite